The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with ...

Type 1 diabetes (T1D), coeliac disease (CD), and autoimmune thyroid disease (AITD), abbreviated as TRIAD diseases, are three ...

Plus: Groupon cofounder’s healthcare venture, investments in CAR-T therapies and the upcoming Forbes Healthcare Summit.

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after ...

Sanofi has announced negotiations with Clayton Dubilier & Rice (CD&R), regarding the potential sale of a 50% controlling ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

A new campaign from Opella, Sanofi’s consumer health unit, is a royal flush. Quite literally: Supporting Opella’s Dulcolax laxative, the Portugal-based campaign sees a diverse series of ...

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private ...

Sanofi in talks to sell 50% stake in Opella for €15 billion ($16.4 billion). Goldman Sachs and Morgan Stanley arrange €6 billion in debt financing for buyers. According to the Bloomberg report ...

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. This newsletter was penned in ...